Nuvation Bio Retained Earnings (Accumulated Deficit) 2020-2024 | NUVB

Nuvation Bio retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Nuvation Bio Retained Earnings (Accumulated Deficit) 2020-2024 | NUVB

Nuvation Bio retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$121.6B
Gilead Sciences (GILD)$111.4B
Bristol Myers Squibb (BMY)$110.2B
Regeneron Pharmaceuticals (REGN)$93B
CSL (CSLLY)$90B
GSK (GSK)$76.4B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$35.3B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$25.3B
Illumina (ILMN)$23.9B
Moderna (MRNA)$21B
BeiGene (BGNE)$19.9B
Genmab (GMAB)$14.9B
Incyte (INCY)$14.7B
Exact Sciences (EXAS)$12.9B
BioMarin Pharmaceutical (BMRN)$12.7B
Vaxcyte (PCVX)$12B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.8B
Insmed (INSM)$11.7B
QIAGEN (QGEN)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.2B
Intra-Cellular Therapies (ITCI)$9.2B
Roivant Sciences (ROIV)$8.6B
Viking Therapeutics (VKTX)$8.1B
Legend Biotech (LEGN)$8.1B